换一批
换一批MET-targeting antibody (emibetuzumab) and kinase inhibitor (merestinib) as single agent or in combination in a cancer model bearing MET exon 14 skipping.
第一作者：
S Betty,Yan
第一单位：
Lilly Research Laboratories, Eli Lilly and Company, DC0522, 307 E. McCarty Street, Indianapolis, IN, 46285, USA. s.betty_yan@lilly.com.
作者：
主题词
动物(Animals);抗体(Antibodies);抗体, 双特异性(Antibodies, Bispecific);细胞系, 肿瘤(Cell Line, Tumor);细胞增殖(Cell Proliferation);外显子(Exons);女(雌)性(Female);人类(Humans);小鼠(Mice);小鼠, 裸(Mice, Nude);蛋白激酶抑制剂(Protein Kinase Inhibitors);原癌基因蛋白质c-met(Proto-Oncogene Proteins c-met);胃肿瘤(Stomach Neoplasms)
DOI
10.1007/s10637-017-0545-x
PMID
29188469
发布时间
2019-03-27
- 浏览18
Investigational new drugs
536-544页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
